Emilie Le Rhun

Emilie Le Rhun

Auto-generated profile, based on publicly available information

Emilie Le Rhun

Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in The Lancet Oncology
Verified
Journal Article
Open access
MWMichael Weller
Michael Weller
MBMartin J. Van Den Bent
Martin J. Van Den Bent
JTJörg C Tonn
Jörg C Tonn
RSRoger Stupp
Roger Stupp
MPMatthias Preusser
Matthias Preusser
WWWolfgang Wick
Wolfgang Wick
The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas. The guideline is based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline. The recommendations focus on pathological and radiological diagnostics, and the main treatment modalities of surgery, radiotherapy, and pharmacotherapy. In this guideline we have also integrated the results from contemporary clinical trials that have changed clinical practice. The guideline aims to provide guidance for diagnostic and management decisions, while limiting unnecessary treatments and costs. The recommendations are a resource for professionals involved in the management of patients with glioma, for patients and caregivers, and for health-care providers in Europe. The implementation of this guideline requires multidisciplinary structures of care, and defined processes of diagnosis and treatment.

16 November 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
WWWolfgang Wick
Wolfgang Wick
TGThierry Gorlia
Thierry Gorlia
MBMartin Bendszus
Martin Bendszus
MTMartin Taphoorn
Martin Taphoorn
FSFelix Sahm
Felix Sahm
MBMartin J. Van Den Bent
Martin J. Van Den Bent
Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. We randomly assigned patients with progression after chemoradiation in a 2:1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients). The methylation status of the promoter of O6-methylguanine–DNA methyltransferase (MGMT) was assessed. Health-related quality of life and neurocognitive function were evaluated at baseline and every 12 weeks. The primary end point of the trial was overall survival. A total of 437 patients underwent randomization. The median number of 6-week treatment cycles was three in the combination group and one in the monotherapy group. With 329 overall survival events (75.3%), the combination therapy did not provide a survival advantage; the median overall survival was 9.1 months (95% confidence interval [CI], 8.1 to 10.1) in the combination group and 8.6 months (95% CI, 7.6 to 10.4) in the monotherapy group (hazard ratio for death, 0.95; 95% CI, 0.74 to 1.21; P=0.65). Locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61; P<0.001). Grade 3 to 5 adverse events occurred in 63.6% of the patients in the combination group and 38.1% of the patients in the monotherapy group. The addition of bevacizumab to lomustine affected neither health-related quality of life nor neurocognitive function. The MGMT status was prognostic. Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann–La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939; Eudra-CT number, 2010-023218-30.)

1 January 2013 in The Lancet Oncology
Verified
Journal Article
Closed access
TBThomas BACHELOT
Thomas BACHELOT
GRGilles Romieu
Gilles Romieu
MCMario Campone
Mario Campone
VDVéronique Diéras
Véronique Diéras
CCClaire Cropet
Claire Cropet
CLCatherine Labbe-Devilliers
Catherine Labbe-Devilliers

1 November 2019 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
EREmilie Le Rhun
Emilie Le Rhun
MPMatthias Preusser
Matthias Preusser
PRPatrick Roth
Patrick Roth
DRDavid A. Reardon
David A. Reardon
MBMartin van Den Bent
Martin van Den Bent
MWMichael Weller
Michael Weller

1 February 2017 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
Riccardo SoffiettiRiccardo Soffietti
Riccardo Soffietti
UAUfuk Abacioglu
Ufuk Abacioglu
BBBrigitta Baumert
Brigitta Baumert
SCStephanie E. Combs
Stephanie E. Combs
SKSara Kinhult
Sara Kinhult
MWMichael Weller
Michael Weller
The management of patients with brain metastases has become a major issue due to the increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014, the European Association of Neuro-Oncology (EANO) created a multidisciplinary Task Force to draw evidence-based guidelines for patients with brain metastases from solid tumors. Here, we present these guidelines, which provide a consensus review of evidence and recommendations for diagnosis by neuroimaging and neuropathology, staging, prognostic factors, and different treatment options. Specifically, we addressed options such as surgery, stereotactic radiosurgery/stereotactic fractionated radiotherapy, whole-brain radiotherapy, chemotherapy and targeted therapy (with particular attention to brain metastases from non–small cell lung cancer, melanoma and breast and renal cancer), and supportive care.

13 July 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ERE. Le Rhun
E. Le Rhun
MWMichael Weller
Michael Weller
DBD. Brandsma
D. Brandsma
MBMartin J. Van Den Bent
Martin J. Van Den Bent
EAEvandro de Azambuja
Evandro de Azambuja
MPM. Preusser
M. Preusser
These EANO–ESMO joint recommendations for the diagnosis and treatment of leptomeningeal metastasis (LM) from solid cancers represent the first European guideline initiative on this topic. LM is defined as the spread of tumour cells within the leptomeninges and the subarachnoid space, is synonymous with ‘neoplastic meningitis’ and can be further denoted by primary tumour as leptomeningeal carcinomatosis, gliomatosis or lymphomatosis. The recommendations address LM from solid tumours, but neither LM from primary brain tumours nor LM from lymphoma or leukaemia. They cover prevention, diagnosis, therapy and follow-up, but not differential diagnosis, adverse effects of therapeutic measures or supportive or palliative care. We propose diagnostic criteria as well as a neuroimaging- and cytopathology-based classification of LM syndromes to derive pragmatic treatment algorithms. We also assign levels of certainty to the diagnosis of LM to provide guidance when to treat (as opposed to when to intensify diagnostic efforts) and on which patients to include in clinical trials. Given the low level of evidence, the recommendations are based more on expert opinion and consensus than on evidence from informative clinical trials. Still, the EANO–ESMO multidisciplinary recommendations shall serve as a valuable source of information for physicians, other health care providers, as well as informed patients and relatives.